Abstract:Cis–trans isomerization of protein plays an important role in protein folding, function, and degradation, which is regulated by peptidyl‐proline isomerases (PPIases). The cis P‐tau but not trans P‐tau is resistant to protein dephosphorylation and degradation and also prone to protein aggregation and serves as an early driver of multiple neurodegenerative disease including Alzheimer disease (AD), traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), and vascular contributions to cognitive impairment and dementia (VCID). Cis P‐tau antibody is the only clinical‐stage therapeutic for AD that has shown the efficacy in animal models of not only AD but also TBI and stroke, which are very early stages of dementia. In this article, we review the role of cis P‐tau in neurodegenerative diseases and its regulation as a potential drug target. A schematic drawing of cis and trans pT231P of tau protein. Cis but not trans P‐tau is induced by multiple stresses and contributes to neurodegenerative diseases. Cis P‐tau is converted into trans P‐tau by Pin1. Conventional tauopathies are a group of disease characterized by tau inclusions in the brains, including Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and certain types of frontotemporal dementia (FTD), among which AD is the most prevalent. Extensive post‐translational modifications, especially hyperphosphorylation, and abnormal aggregation of tau protein underlie tauopathy. Cis–trans isomerization of protein plays an important role in protein folding, function, and degradation, which is regulated by peptidyl‐proline isomerases (PPIases). Peptidyl‐prolyl cis–trans isomerase NIMA‐interacting 1 (Pin1), the only PPIase found to isomerize Pro following phosphorylated Ser or Thr residues, alters phosphorylated tau protein conformation at pT231‐P motif. The cis P‐tau but not trans P‐tau serves as an early driver of multiple neurodegenerative disease, encompassing AD, traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), and vascular contributions to cognitive impairment and dementia (VCID). Cis but not trans P‐tau is resistant to protein dephosphorylation and degradation, and also prone to protein aggregation. Cis P‐tau loses its ability to stabilize microtubule, causing and spreading tauopathy mainly in axons, a pathological process called cistauosis. The conformation‐specific monoclonal antibody that targets only the cis P‐tau serves as a very early diagnosis method and a potential treatment of not only conventional tauopathies but also nonconventional tauopathies such as VCID, with clinical trials ongoing. Notably, cis P‐tau antibody is the only clinical‐stage Alzheimer's therapeutic that has shown the efficacy in animal models of not only AD but also TBI and stroke, which are very early stages of dementia. Here we review the identification and pathological consequences of cis pt231‐tau, the role of its regulator Pin1, as well as the clinical implication of cis pt231‐tau conformation‐specific antibody in conventional and nonconventional tauopathies.

cis P-tau Accumulation Triggers Neurodegeneration after Ischemic Stroke

New Pieces of the Puzzle in the Development of Neurofibrillary Tangles in Post-Ischemic Brain Neurodegeneration of the Alzheimer's Disease-like Type

Cerebral hypoperfusion reduces tau accumulation

Function and regulation of cis P‐tau in the pathogenesis and treatment of conventional and nonconventional tauopathies

Proteomic and Genomic Changes in Tau Protein, Which Are Associated with Alzheimer’s Disease after Ischemia-Reperfusion Brain Injury

Modifications of tau protein after cerebral ischemia and reperfusion in rats are similar to those occurring in Alzheimer’s disease – Hyperphosphorylation and cleavage of 4- and 3-repeat tau

Brain Ischemia as a Prelude to Alzheimer's Disease

Soluble pathogenic tau enters brain vascular endothelial cells and drives cellular senescence and brain microvascular dysfunction in a mouse model of tauopathy

Tau Pathology Triggered by Spinal Cord Injury Can Play a Critical Role in the Neurotrauma Development

Pathological Tau From Alzheimer's Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau in vivo .

Influence of Tau on Neurotoxicity and Cerebral Vasculature Impairment Associated with Alzheimer's Disease

Total Tau Protein Mediates the Association of Ischemic Cerebrovascular Disease with Cognitive Decline

Brain Vasculature Accumulates Tau and Is Spatially Related to Tau Tangle Pathology in Alzheimer’s Disease

Abnormal tau induces cognitive impairment through two different mechanisms: synaptic dysfunction and neuronal loss

Molecular characterization of genes encoding the quinolone resistance determining regions of Malaysian Streptococcus pneumoniae strains.

Carbamazepine and bone mineral metabolism

Locus coeruleus vulnerability to tau hyperphosphorylation in a rat model

An Investigation on the Optimization and Scaling of Complementary SiGe HBTs

Hyperphosphorylation of Tau Protein in Hippocampus of Central Insulin-Resistant Rats is Associated with Cognitive Impairment

Tau accumulation triggers STAT1-dependent memory deficits by suppressing NMDA receptor expression

Reducing acetylated tau is neuroprotective in brain injury